TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06477692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENI using IMRT with or without chemotherapy
Description: This study is a phase II single-blinded randomized trial comparing standard ENI with involved nodal radiotherapy. INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ENI using IMRT with or without chemotherapy
Description: This study is a phase II single-blinded randomized trial comparing standard ENI with involved nodal radiotherapy. INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: INRT
Description: INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: ENI
Description: ENI using IMRT with or without chemotherapy
Study: NCT04933656

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: one 24 hr cycle of meals at a 2000 kcal level + three serving sugar sweetened beverage
Description: 170 grams added sugar
Study: NCT06508216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: Patients in module 1 \& 2 will receive Datopotamab Deruxtecan (Dato-DXd) 6mg/kg every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: Patients in module 1 \& 2 will receive Datopotamab Deruxtecan (Dato-DXd) 6mg/kg every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients in module 2 only will receive Durvalumab 1120mg every 21 days
Study: NCT05723562

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.
Study: NCT06580249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: The true stimulus group acted directly, whereas the pseudo stimulus group reversed the head to produce no effect. Both groups were treated with sertraline medication。

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: The true stimulus group acted directly, whereas the pseudo stimulus group reversed the head to produce no effect. Both groups were treated with sertraline medication。
Study: NCT05643196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLIFUS
Description: The Sonicator-1000 system will non-invasively deliver ultrasound sonications transcranially that selectively target specific areas of the brain using a neuronavigation system and the participant's MRI brain scan. The sonication parameters follow FDA and Electrotechnical Technical Commission regulation standards for diagnostic and therapeutic ultrasound.
Study: NCT05070858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab + Cemdisiran
Description: Subcutaneous administration as described in the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab + Cemdisiran
Description: Subcutaneous administration as described in the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: SC administration as described in the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: SC administration as described in the protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC administration as described in the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: SC administration as described in the protocol
Study: NCT05643196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLIFUS
Description: The Sonicator-1000 system will non-invasively deliver ultrasound sonications transcranially that selectively target specific areas of the brain using a neuronavigation system and the participant's MRI brain scan. The sonication parameters follow FDA and Electrotechnical Technical Commission regulation standards for diagnostic and therapeutic ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham PLIFUS
Description: Sham PLIFUS treatment delivers noise and patient experience that is identical to PLIFUS with Sonicator-1000 system.
Study: NCT06779409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wingate test
Description: 30 second maximal effort cycling test, with resistance at 7.5% bodyweight
Study: NCT05643196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham PLIFUS
Description: Sham PLIFUS treatment delivers noise and patient experience that is identical to PLIFUS with Sonicator-1000 system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: A total of 5 MRIs will be performed using a Siemens 3T Prisma; one prior to the intervention visit, and one preceding and one immediately after each of the two sonication/sham visits.
Study: NCT04036331

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brenner FIT Standard
Description: After referral, families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and physical activity specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, physical activity, and parenting. Specialized visits with the physical activity specialist or dietician are scheduled as pertinent issues arise. Clinic visits include individualized goal setting (for behaviors family/clinician have agreed to address), healthy eating and physical activity education, and behavioral counseling to implement changes at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: By Design Essentials
Description: A dietitian provides each participant with a detailed program manual that describes the prescribed diet. The dietitian utilizes standard behavioral techniques to promote lifestyle behavior changes that enable participants to implement and maintain behaviors necessary to adhere to the dietary prescription. Participants also receive a standard exercise program designed to promote exercise energy expenditure of approximately 600 kilocalories\*/week. The exercise prescription includes resistance training for 2 days per week and aerobic training for 3 days per week, to meet a 600 kilocalories\*/week expenditure goal. Behaviorists meet with participants to provide individual and group-based counseling to learn the skills necessary to adopt the prescribed dietary pattern and exercise plans. Group sessions will be delivered consecutively over 6 months (20 total; 1.5 hours each).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyad Plus
Description: This will include all components of the standard Brenner FIT program and By Design Essentials.~In addition, group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. Dyads will attend 6 meetings that will last approximately 1 hour each.
Study: NCT05777993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Tablets
Study: NCT05188170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy
Study: NCT06439576

Intervention type: DRUG
Intervention: Faricimab
Description: The dosing and treatment duration of the studied medicinal product is at the discretion of the physician in accordance with clinical practice and labeling in China.
Study: NCT05643196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: A total of 5 MRIs will be performed using a Siemens 3T Prisma; one prior to the intervention visit, and one preceding and one immediately after each of the two sonication/sham visits.
Study: NCT06212063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cadet Health
Description: Integrated physical and mental optimization training program used as tool for young individuals readying themselves to join the military
Study: NCT05457907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound device
Description: Low energy ultrasound therapy will be administered to the spleen
Study: NCT05088746

Intervention type: PROCEDURE
Intervention: Non-surgical periodontal therapy
Description: NSPT will be performed following the principles of minimally invasive non-surgical therapy (MINST) described by Nibali et al. (Nibali et al., 2015, Nibali et al., 2019)
Study: NCT06561386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days
Study: NCT06396260

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diffusion Kurtosis Imaging (DKI)
Description: Non-invasive MRI sequence which extracts information of diffusion signals from complex brain tissue

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diffusion Kurtosis Imaging (DKI)
Description: Non-invasive MRI sequence which extracts information of diffusion signals from complex brain tissue

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diffusion Kurtosis Imaging (DKI)
Description: Non-invasive MRI sequence which extracts information of diffusion signals from complex brain tissue

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resting State Magnetoencephalography
Description: Non-invasive method of measuring resting state brain activity through magnetoencephalography (MEG)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resting State Magnetoencephalography
Description: Non-invasive method of measuring resting state brain activity through magnetoencephalography (MEG)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resting State Magnetoencephalography
Description: Non-invasive method of measuring resting state brain activity through magnetoencephalography (MEG)
Study: NCT05904496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-30813
Description: Specified dose administered on specified days
Study: NCT06778382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oligometastasis Treatment
Description: Oligometastatic Radiotherapy Group: Patients will receive radiotherapy to lung lesions, with the lung metastases outlined as the Gross Tumor Volume (GTV). The prescribed dose will be based on a BED (Biologically Effective Dose) of 72-100 Gy, using either conventional split, macrodissected, or SBRT (Stereotactic Body Radiation Therapy) at the investigator's discretion. No systemic therapy will be administered.~Oligometastatic Radiofrequency Ablation Group: For lesions suitable for radiofrequency ablation, this will be performed in consultation with the Department of Interventional Medicine, considering patient and family preferences. Systemic therapy will not be given.~Oligometastatic Surgery Group: For lesions suitable for surgical resection, patients will undergo surgery after consultation with the Department of Surgery. No systemic therapy will be performed.
Study: NCT06778122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High efficiency particulate air filtration system (nightly administration)
Description: Portable air purifier is programmed to provide a dose of filtered air at 275 m³/h nightly for at least 7 hours consecutive within a time window between 10:00 p.m. and 10:00 a.m. Air purifier is set up with active filters (HyperHEPA technology). Dose adjustments are permitted in the study where noise disturbance is an issue for participants. The air filtration therapy will be delivered in doses decreasing sequentially in terms of speed mode. Participants will be instructed to keep doors and windows of the bedroom closed during each session at night, and to follow a similar bedtime routine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High efficiency particulate air filtration system (nightly and daily administration)
Description: Portable air purifier set up with active filters (HyperHEPA technology) is continuously in operation (24 hours for 14 days) at 275 m³/h in bedrooms with the door and windows closed. During this open-labell phase, the participants will be asked to remain in the bedroom for as long as possible and to keep an activity log for the outdoor locations. Dose adjustments are permitted.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Air filtration system without filters (sham)
Description: Portable air purifier is programmed to provide a dose of filtered air at 275 m³/h nightly for at least 7 hours consecutive within a time window between 10:00 p.m. and 10:00 a.m. Air purifier is set up with a sham filter, which is identical in appearance and noise as the HyperHEPA filter (active filter) when the air purifier is in operation. Dose adjustments are permitted in the study where noise disturbance is an issue for participants.
Study: NCT06779448

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of objective and subjective stress parameters caused by local anesthesia during treatments
Description: Patients were divided according to the randomization procedure. infiltration anesthesia (Maxicaine Forte, Artikain, VEM Drug, Turkey) was performed with a 20-gauge needle. Following the administration of anesthetic, an appropriate size rubber dam and metal clamp was placed i and pit and fissure sealant was applied. The stress parameters of the subjects were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
Study: NCT05905835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synaptic Cryoablation System
Description: The Synaptic Cryo Balloon must be used to isolate all targeted pulmonary veins. Entrance block will be confirmed in all targeted pulmonary veins (PVs) after a 20-minute waiting period or provocative testing with adenosine or isoproterenol. Any additional ablation in the LA beside PV isolation is not allowed in this protocol. Additional ablation of the cavo-tricuspid isthmus (CTI) with a conventional market-approved RF catheter is allowed only in case a typical atrial flutter is documented in prior patient history or occurs during the case (either spontaneously or inducible).
Study: NCT06502132

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education Group
Description: Patients whose surgery has been postponed will be educated by the researcher through a booklet regarding the waiting process. The education includes information such as anxiety management, pain management, and re-surgery planning. The booklet consists of 22 pages and a copy is given to each patient in this group. The education lasts between 15-20 minutes and the patients' questions are answered. It is applied in a single session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Touch Group
Description: Therapeutic touch application is applied as a single session and lasts approximately 20-25 minutes. The therapeutic touch that emerges from the artistic aspect of nursing is an energybased practice that does not involve physical contact. Therapeutic touch is a conscious and compassionate effort to direct the flow of one's universal life energy to healing by influencing this energy.
Study: NCT06362655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intervention study. In this intervention study for teachers, a 5-month continuous training program will be included that will improve teaching style and promote teaching training. It will also strengthen teaching competencies to create teaching improvement strategies affecting PEaH and interpersonal and personal factors. This is expected to improve schoolchildren's AB, even when they are not directly influenced. The program will be designed according to the results of the cross-sectional study. The greatest associations found between the three proposed factors (school, interpersonal and personal factors) and schoolchildren AB will be sought. In addition, the characteristics of the schools and the possibilities of time and physical spaces available will be taken into account. This information will be recorded through validated questionnaires and interviews in the pre-test, post-test 1 and after follow-up post-test 2.
Study: NCT05904496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-30813
Description: Specified dose administered on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Specified dose administered on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Specified dose administered on specified days
Study: NCT06561828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous Theta Burst Stimulation (cTBS)
Description: Continuous theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for a total of 600 pulses per site).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous Theta Burst Stimulation (cTBS)
Description: Continuous theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for a total of 600 pulses per site).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous Theta Burst Stimulation (cTBS)
Description: Continuous theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for a total of 600 pulses per site).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous Theta Burst Stimulation (cTBS)
Description: Continuous theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for a total of 600 pulses per site).
Study: NCT06779435

Intervention type: DRUG
Intervention: Low intensity treatment options
Description: Reference options for a combined regimen include C-R2, C-R-mini-CHOP, etc.~Subjects whose efficacy is assessed as CR after the end of induction therapy will enter consolidation therapy. Tucidinostat maintenance therapy or autologous hematopoietic stem cell transplantation may be an option. Tucidinostat maintenance therapy will be performed every 3 weeks. .Single-drug maintenance is recommended to last 24 weeks

Intervention type: DRUG
Intervention: Conventional immunochemotherapy regimen
Description: Reference options for a combined regimen include CR-CHOP, C-Pola-R-CHP, etc.~Subjects whose efficacy is assessed as CR after the end of induction therapy will enter consolidation therapy. Tucidinostat maintenance therapy or autologous hematopoietic stem cell transplantation may be an option. Tucidinostat maintenance therapy will be performed every 3 weeks. Single-drug maintenance is recommended to last 24 weeks
Study: NCT06779552

Intervention type: DEVICE
Intervention: CardioMEMS HF System
Description: PA Pressure Sensor
Study: NCT06275919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib 40 MG Oral Tablet
Description: REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
Study: NCT06561828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous Theta Burst Stimulation (cTBS)
Description: Continuous theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for a total of 600 pulses per site).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent Theta Burst Stimulation (iTBS)
Description: Intermittent theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for 2 seconds followed by a break of 8 seconds for a total of 600 pulses per site).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent Theta Burst Stimulation (iTBS)
Description: Intermittent theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for 2 seconds followed by a break of 8 seconds for a total of 600 pulses per site).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent Theta Burst Stimulation (iTBS)
Description: Intermittent theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for 2 seconds followed by a break of 8 seconds for a total of 600 pulses per site).